Q 3 2024 Main Objective 1- Achieve 100% of total target 2-Achieve 3,969 unit (1,323/month) super seas /Q3 3 -Make significant Improvement of all line 1 Products MKT Share 4 -Make significant horizontal growth in Q3 2024 over Q2 in all line 1 portfolio 5- convert 3 Drs / month form A - to A + Charles Pfizer Charles Earhart
Total Sales June.2024 Upper Egypt 1
Total June 2024 Sales/product Upper Egypt 1
june - 2024 Sales / Rep. Upper Egypt 1
Total june 2024 Sales/product Fayoum & beni suef
Total june 2024 Sales/product Menia 2
Total june - 2024 Sales/product Menia 1 ( vacant )
General tactics Arrangement AV actions with juniors and seniors drs in ped, IM and chest department in all am account Arrangement RTD with ped, IM and chest KOL drs Pharmacy campaigns to make seeding and increase sales Converting 3 Drs / month / medical rep. from A – to A + Apply the horizontal & vertical growth strategy monthly to make significant increase in sales trend of each product Telesales : using commercial tactics e.g. points system
GAP analysis Vacant Menia 1 pentamix ibn sina only Shortage debacolev , nono water in distributer ( POS) UCP Low stock of debacolev & super seas & nono In ibn sina --- zero stock in POS Sales rep. for Upper egypt 1
7-2024 Forecast
Action plan Ser What when Who Impact 1 Group meeting el qusia during july Dr.Mohamed rabea Increase nono + pentamix 2 RTD chest Drs mallaway During Q3 Dr.Mohamed rabea Super seas Collecting orders from pharmacies per day from all disributers During Q3 UE1 team All products RTD fayoum KOL drs During Q3 Dr.Mohamed rabea Super seas 3 Group meeting el shamla assiut During july Dr.Mohamed rabea Pentamix & nono 4 Rx printing During June Upper egypt 1 L500+750+K+pentamix 5